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Abstract
Background Sorafenib significantly improves survival in
patients with advanced hepatocellular carcinoma (HCC).
This phase IV study assessed sorafenib efficacy/safety in
Taiwanese patients with advanced HCC and Child–Pugh A
status.
Methods All patients received 400 mg sorafenib BID.
Safety, efficacy, sorafenib pharmacokinetics, and Child–
Pugh progression were evaluated. A hand-foot skin
reaction (HFSR) prevention substudy assessed HFSR
incidence and grade/severity and time to HFSR in 29 and
34 patients randomized to corticosteroid and noncorti-
costeroid ointments, respectively, and in 88 nonran-
domized patients.
Results The 151 patients included 120 (80%) male patients
and 81 (54%) with stage IV disease. Mean sorafenib dose
was 626 mg/day, and median treatment duration was
4.2 months. Median overall survival (OS), progression-free
survival, and time to progression (TTP) were 8.6, 2.7, and
3.8 months, respectively. Disease control and response
rates (partial responses only) were 48 and 6.6%, respec-
tively. Median TTP from Child–Pugh A to B/C was
88 days. Drug-related adverse events (AEs) occurred in
89.4% of patients; none were new or unexpected. The most
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frequent grade C3 drug-related, treatment-emergent AEs
were HFSR (13.2%), diarrhea (11.9%), and hypertension
(6.6%). Corticosteroid ointment tended to reduce the
severity and incidence of all HFSR-associated parameters.
Pharmacokinetic exposure was unaltered by Child–Pugh
progression. The final pharmacokinetic model predicted
13.1 and 33.8% reductions in sorafenib exposure over 6
and 12 months, respectively.
Conclusions There was a trend of longer OS and TTP in
Taiwanese patients with advanced HCC compared with
patients with advanced HCC in the Asia–Pacific trial.
Sorafenib exposure did not correlate with liver function.
Reduced pharmacokinetic exposure over time was unre-
lated to reduced or interrupted dosing.
Keywords Sorafenib  Advanced hepatocellular
carcinoma  Metastatic hepatocellular carcinoma 
Taiwanese patients  Overall survival  Time to progression
Introduction
Hepatocellular carcinoma (HCC) is the sixth most common
cancer worldwide and the third most common in the Asia–
Pacific region [1, 2]. Geographical differences in HCC
incidence are largely due to variations in hepatitis B and C
infection [3, 4]. In East Asia, including Taiwan, where
hepatitis B virus (HBV) is endemic, the incidence rate of
HCC is 20–28 per 100,000 people. Approximately 10–20%
of cases of HCC occur in patients with chronic HBV
infection in the absence of cirrhosis.
Two randomized, placebo-controlled, phase III trials,
the Sorafenib HCC Assessment Randomized Protocol
(SHARP) and the Sorafenib Asia–Pacific (Sorafenib AP)
trials, showed that the multikinase inhibitor sorafenib sig-
nificantly improves overall survival (OS) and progression-
free survival (PFS) in patients with advanced HCC [5, 6].
Based on these results, sorafenib was approved as systemic
treatment for patients with advanced HCC and remains the
only globally approved systemic treatment for this disease.
As a post-approval commitment in Taiwan, 151 patients
were enrolled in this phase IV, single-arm study [Hepato-
cellular carcinoma–Advanced stage–sorafenib Trial in
Taiwanese patients (HATT)] to confirm the efficacy and
safety of sorafenib. The requested number of patients was
based on the number of patients from the mainland of
China who were treated in the phase 3 Asia–Pacific study
(NCT00492752), which was 151 of the 226 randomized
patients [5]. The main objective of the post-authorization
study was to evaluate the safety and efficacy profile of
sorafenib and to evaluate Child–Pugh status progression in
Taiwanese patients with advanced HCC treated with sor-
afenib. The main study did not have a primary endpoint.
Another objective of this main study was to assess the
pharmacokinetics of sorafenib in patients with HCC. A
substudy of hand-foot skin reaction (HFSR) prevention
assessed HFSR incidence and grade/severity and time to
HFSR in patients randomized to corticosteroid and non-
corticosteroid ointment and in a group of nonrandomized,
untreated patients.
Methods
This prospective, open-label, single-arm, post-authoriza-
tion study was conducted across seven sites in Taiwan in
patients with advanced HCC. All patients meeting entry
criteria received sorafenib 400 mg (2 9 200-mg tablets)
twice daily (BID) on a continuous schedule. For the pur-
pose of data recording, treatment period was divided into
21-day cycles. Treatment continued beyond radiologic
progression, provided the subject derived clinical benefit,
as judged by the treating physician.
Ethical considerations
The trial protocol was approved by the institutional review
boards of all seven institutions. All patients provided
written informed consent. The trial has been registered at
clinicaltrials.gov as NCT01098760.
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Inclusion criteria
Patients aged C18 years were included if they had cyto-
logically or histologically documented, unresectable ad-
vanced and/or metastatic HCC not amenable to local
treatment methods, with at least one tumor lesion that
could be measured accurately in at least one dimension and
had not been treated with local therapy. HCC in cirrhotic
patients was diagnosed by American Association for the
Study of Liver Disease criteria; noncirrhotic patients
required histological or cytologic confirmation. Patients
who previously received local therapy (e.g., surgery, radi-
ation, hepatic artery embolization, transarterial chemoem-
bolization, radiofrequency ablation, percutaneous ethanol
injection, or cryoablation) were deemed eligible, but local
therapy had to be completed at least 4 weeks before study
entry, and all toxic effects of any prior local treatments had
to have resolved. Moreover, previously treated lesions
could not be selected as target lesions. Other inclusion
criteria included Child–Pugh Class A, Eastern Cooperative
Oncology Group performance status of 0–2, and life
expectancy C 12 weeks. The first patient’s first visit was in
August 2010 and the last patient’s first visit was in June
2012.
Exclusion criteria
Patients were excluded if they had previous or concurrent
cancer, unless curatively treated [3 years before study
entry; renal failure requiring dialysis; a history of cardiac
disease, including congestive heart failure, active coro-
nary artery disease, or cardiac arrhythmias; or uncon-
trolled hypertension (systolic blood pressure[150 mmHg
or diastolic blood pressure [90 mmHg). Also excluded
were patients with active, clinically serious infections
[except for HBV/hepatitis C virus (HCV)]; central ner-
vous system tumors; clinically significant gastrointestinal
bleeding \30 days before study entry; history of organ
allograft transplantation; Child–Pugh Class B or C liver
status; or uncontrolled ascites. Patients previously treated
with yttrium-90 spheres, those with clinically significant
peripheral vascular disease or a history of substance abuse
or psychological conditions interfering with participation,
and patients unable to take oral medications were also
excluded.
Dose modifications
All patients were initially treated with 400 mg sorafenib
BID. Reductions to 400 mg once daily and 400 mg every
other day (QOD) were permitted for clinically significant
hematologic and nonhematologic toxicities. Treatment was
decreased one dose level for grade 3 hematologic
toxicities. Treatment was interrupted in patients with grade
4 hematologic toxicities and in patients with grade 3 non-
hematologic toxicities (except skin toxicity and hyperten-
sion) until they achieved grade B2 with treatment resumed
at one lower dose level. Treatment was also discontinued in
patients with grade 4 nonhematologic toxicities and in
patients who would have required further dose reductions
beyond 400 mg QOD. In patients who experienced two or
more toxicities, reductions were according to the toxicity
with the highest grade; alternatively, if both toxicities were
of equal grade, dose was reduced according to the toxicity
deemed most causally related to study treatment. Increases
were permitted in patients who previously had dose
reductions and remained on stable doses for C3 weeks
without further toxicities, although only one such increase
per patient was permitted.
Safety and efficacy assessments
Safety was evaluated at screening (within 28 days of first
dose of study drug), before dosing on the first day of study
drug administration, and before dosing every 3 weeks
(±7 days). Tumors were assessed within 28 days of the
start of study drug using CT or MRI scans. For the purpose
of data recording, the treatment period was divided into
3-week cycles. Tumor measurements and evaluation of
tumor response were performed within the last 7 days of
every other treatment cycle, beginning with the second
cycle. Child–Pugh status was determined at screening and
on day 1 of each cycle.
Follow-up
After completion of study drug treatment, patients were
contacted every 3 months to determine survival status.
Follow-up was continued until 6 months after the first
treatment of the last patient. For regulatory purposes, the
end of the trial was defined as 6 months after the first
treatment of the last patient but not before 106 patients had
died.
Pharmacokinetic analysis
After enrollment started, the study protocol was amended
to include a steady-state pharmacokinetic analysis, as
requested by the Taiwan Department of Health. Sorafenib
pharmacokinetics were assessed in a subpopulation of 85
patients. Blood samples were collected on day 1 of each
21-day cycle, starting with cycle 2, to assess sorafenib
exposure concurrently with each determination of Child–
Pugh status. Sorafenib concentrations in plasma were
determined by high-pressure liquid chromatography and
tandem mass spectrometry. Summary statistics were
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generated describing sorafenib plasma concentrations of all
pharmacokinetics samples at a given Child–Pugh score.
Plasma sorafenib concentrations were analyzed using a
previously defined population pharmacokinetic model
[7, 8] and the software program, NONMEM v.7.2 (ICON,
Dublin, Ireland). Briefly, the previously developed model
applied to the HATT data used a 1-compartment model
with three sequential transit absorption compartments and
included sex, body weight, body mass index, race (Asian/
nonAsian), Child–Pugh score, age, liver transaminases,
albumin, bilirubin, alkaline phosphatase, lactate dehydro-
genase, serum glutamic oxaloacetic transaminase, serum
glutamic pyruvic transaminase, prothrombin time, crea-
tinine clearance, co-medication with CYP3A4 or UGT1A9
inducers or inhibitors, or thyroxine as a covariate for sor-
afenib apparent clearance (CL/F). For the current analyses,
gender was the only covariate included in the model
because it was the one covariate that significantly influ-
enced CL/F in the meta-analysis that was performed to
develop the population pharmacokinetic model. Predicted
sorafenib concentrations were calculated based on daily
doses and dose reductions, interruptions, and discontinua-
tions. Observed and predicted sorafenib concentrations
from the final model were compared, as were changes over
time.
Incidence of and time to hand-foot skin reaction
During the HATT trial, the study protocol was amended to
include assessment of the impact of two different ointments
on HFSR prevention. Beginning at the start of treatment,
29 patients were randomized to a corticosteroid and 34 to a
noncorticosteroid ointment, to be applied twice daily to
soles and palms for 21 days. The rates of HFSR after 3 and
6 weeks and overall, as well as time to HFSR and
grade/severity of HFSR, were compared in these two
groups and with a group of 88 patients enrolled before the
start of the HFSR prevention substudy. Exposure to sor-
afenib was also assessed in these three subgroups, as
measured by duration of treatment, total dose, and number
of dose modifications.
Statistical analysis
Demographic variables and baseline characteristics were
summarized descriptively for all patients in the intent-to-
treat population. Continuous variables were reported as
mean ± standard deviation or medium (minimum, maxi-
mum), and categorical variables were reported as fre-
quency (%). Time to event variables, including OS, PFS,
time to progression (TTP), and time from Child–Pugh A to
Child–Pugh B/C, were assessed by the Kaplan–Meier
method and compared by the log-rank test. Treatment-
emergent adverse events (AEs), drug-related AEs, AEs
leading to premature termination, dose reductions and
interruptions, serious AEs (SAEs), and laboratory param-
eters were summarized using descriptive statistics for
safety.
Results
Patient characteristics and exposure to sorafenib
Most patients (54%) had stage IV disease at study entry
(Table 1). The primary causes of HCC in these patients
were HBV infection (n = 81, 53.6%) and HCV infection
(n = 41, 27.2%; Table 1). Of the 151 patients, 23 (15.3%)
were continuing treatment at the time of database cutoff,
whereas 128 (84.8%) terminated treatment, most for AEs,
disease progression/recurrence, and withdrawal of consent
(Fig. 1).
Although the study protocol required that all patients be
Child–Pugh class A, two (1.3%) were Child–Pugh class B
at baseline. Protocol deviations were documented for both
patients.
Assessment of time of patient exposure to sorafenib
showed that the median duration of treatment was
18.1 weeks (range, 0.3–124 weeks), and the mean ± SD
duration of treatment was 29.9 ± 30.3 weeks. During this
time, patients received a median 661.5 mg/day (range,
211.5–800 mg/day) and a mean ± SD of
625.9 ± 170.3 mg/day sorafenib. Of the 151 patients, 112
(74.2%) required dose reductions, and 99 (65.8%) required
dose interruptions.
Efficacy
Median OS was 8.6 months (95% CI, 6.4–10.1 months);
median PFS was 2.7 months (95% CI, 2.6–3.9 months);
and median TTP was 3.8 months (95% CI,
2.6–4.1 months; Fig. 2).
Ten patients (6.6%) showed a partial response to treat-
ment, and 62 (41.1%) had confirmed stable disease. Thus,
the overall response rate was 6.6% and the disease control
rate was 47.7%. Descriptive analysis of mean alpha feto-
protein (AFP) levels showed that AFP levels were variable
but decreased from baseline by treatment cycle 6 (Sup-
plemental Fig. 1). At the end of treatment, 73 patients were
classified as Child–Pugh A, 50 as Child–Pugh B, and 12 as
Child–Pugh C. The median time to worsening of liver
function, from Child–Pugh A to first detection of Child–
Pugh B or C, was 2.9 months (95% CI, 1.9–4.8 months)
(Fig. 2). Child–Pugh scores of individual patients did not
consistently progress over time, from A to B, B to C, and A
to C; rather, Child–Pugh scores varied within a patient
202 Hepatol Int (2017) 11:199–208
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between visits, with some patients showing improvements
after initial worsening and others showing progressive
deterioration.
Safety
There were no unexpected AEs. Drug-related treatment-
emergent AEs were reported in 135 patients (89.4%), with
grade 1/2 drug-related AEs occurring in 63 patients
(41.7%) and grade 3/4 drug-related AEs occurring in 72
patients (47.7%) (Table 2). The most frequently reported
drug-related, treatment-emergent AEs in this trial were
HFSR (64.9%), diarrhea (45.0%), and ascites (27.2%),
whereas the most frequently reported grade 3 drug-related,
treatment-emergent AEs were HFSR (13.2%), diarrhea
(11.9%), and hypertension (6.6%). Treatment-emergent
SAEs were reported in 110 patients (72.8%), and drug-
related treatment-emergent SAEs in 14 (9.3%). Grades 3
and 4 drug-related, treatment-emergent SAEs were repor-
ted in 10 (6.6%) and 3 (2.0%) patients, respectively, but
there were no drug-related, treatment-emergent grade 5
SAEs.
Pharmacokinetics
Of the 151 patients, 85 (56.3%) provided a total of 847
plasma samples for pharmacokinetic analysis. Median
sorafenib concentrations at the time of pharmacokinetic
sampling of patients classified as Child–Pugh A, B, and C
were 3.72 mg/L (range, 0.0162–15.6 mg/L), 2.90 mg/L
(range, 0.0124–15.6 mg/L), and 3.29 mg/L (range,
0.0287–7.44 mg/L), respectively (Supplemental Fig. 2).
Application to the HATT trial of a population pharma-
cokinetic model developed from 10 phase I to III trials of
sorafenib in healthy volunteers and in patients with renal
cell carcinoma, HCC, differentiated thyroid cancer, and
other tumor types, including patient sex as a covariate with
sorafenib CL/F [8], suggested a trend toward decreasing
sorafenib concentrations over time that was not accounted
for by the model (Supplemental Fig. 3). Examination of
sex as a covariate indicated a 40.5% lower overall CL/F in
female than in male patients. Linear and power relation-
ships for a change in clearance or bioavailability over time
were tested, with the power model providing the best fit.
Table 1 Demographic characteristics and disease history of Tai-
wanese patients with HCC
Characteristics Total patients (n = 151)
Median age, year (range) 62.0 (28–97)
Male patients, n (%) 120 (79.5)
Mean ± SD weight, kg 62.35 ± 10.55
Mean ± SD BMI, kg/m2 23.58 ± 3.26
Etiology, n (%)
Hepatitis B 81 (53.6)
Hepatitis C 41 (27.2)
Alcohol use 6 (4.0)
Hepatitis B and C 5 (3.3)
Hepatitis B and alcohol 3 (2.0)
Nonalcoholic steatohepatitis 2 (1.3)
Hepatitis C and alcohol 1 (0.7)
Hepatitis B and C and alcohol 1 (0.7)
Unknown 11 (7.3)




Child–Pugh classification, n (%)
A 149 (98.7)
B 2 (1.3)











Liver cirrhosis 144 (95.4)
AFP[200 ng/mL 99 (65.6)
AFP alpha-fetoprotein, BMI body mass index, ECOG PS Eastern
Cooperative Oncology Group performance score, HCC hepatocellular









1 lost to follow-up
2 protocol violation
192 patients screened
Fig. 1 CONSORT diagram
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Inclusion of albumin and bilirubin as covariates improved
the model fit, whereas alkaline phosphatase, prothrombin
time, international normalized ratio, serum glutamic
oxaloacetic transaminase, serum glutamic pyruvic
transaminase, and Child–Pugh score did not affect sor-
afenib exposure. Both bilirubin and albumin concentrations
were positively correlated with sorafenib concentrations,
although only bilirubin showed a time dependence, with
sorafenib concentrations and bilirubin levels decreasing
together over time. Using the final population pharma-
cokinetic model, the observed and predicted plasma sor-
afenib concentrations in individual patients demonstrated
concordance over the entire time range studied (Table 3,
Fig. 3). The final pharmacokinetic model predicted reduc-
tions of 13.1% and 33.8% in sorafenib exposure over 6 and
12 months, respectively.
Hand-foot skin reaction substudy
The incidence of overall HFSR and at weeks 3 and 6 did
not differ significantly between patients randomized to
corticosteroid and noncorticosteroid ointments (Table 4).
HFSR incidence rates were also not significantly different
between patients randomized to corticosteroid cream and
those not treated with ointment (Table 4). HFSR scores at 3












































































Median TTP: 3.8 months 
95% Cl: 2.63–4.08 months


















Median OS: 8.6 months 




Median PFS: 2.7 months 
95% Cl: 2.60–3.91 months 
Sorafenib
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95% Cl: 1.87–4.8 months 
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Fig. 2 Efficacy outcomes. Kaplan–Meier plots of a OS, b PFS,
c TTP, and d time from Child–Pugh A to Child–Pugh B/C liver status
in patients enrolled in the HATT trial. OS overall survival, PFS
progression-free survival, TTP time to progression, HATT Hepato-
cellular Carcinoma–Advanced Stage–Sorafenib Trial in Taiwanese
patients
Table 2 Percentage of patients with drug-related, treatment-emer-
gent AEs observed in[5% of patients






Rash maculopapular 11.3 0.7/0
Platelet count decreased 9.9 4.0/1.3
Pruritus 8.6 0.7/0
AST increased 6.6 4.0/1.3
Anorexia 6.0 0/0
Hoarseness 5.3 0/0
Weight loss 5.3 0/0
AEs adverse events, AST aspartate aminotransferase, HFSR hand-foot
skin reaction
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and 6 weeks did not differ significantly between patients
randomized to corticosteroid and noncorticosteroid treat-
ment, and between patients randomized to corticosteroid
treatment and those not treated with ointment (Table 4).
However, overall HFSR scores were significantly different
between patients randomized to corticosteroid cream and
noncorticosteroid ointments (0.83 vs. 1.26, p = 0.031) and
between patients randomized to corticosteroid cream and
those not treated with ointment (0.83 vs. 1.24, p = 0.038)
(Table 4). Time to HFSR was longer in the group treated
with corticosteroid cream (41 days) than in the group
treated with noncorticosteroid cream (22 days) and the
untreated control group (21 days), although these differ-
ences were not statistically significant. The incidence of
grade 3 HFSR was low in both arms of the substudy (5.9%
in the noncorticosteroid group and 0% in the corticosteroid
group; no grade 4 or 5 events were reported). However, the
incidence of grade 3 HFSR (20.5%) was higher in the
nonointment group (Table 4). Corticosteroid treatment
tended to reduce the severity and incidence of all HFSR-
associated parameters (Fig. 4).
Discussion
As a post-approval commitment, 151 patients from Taiwan
were enrolled in this phase IV, single-arm study to confirm
the efficacy and safety of 400 mg BID sorafenib in patients
with advanced HCC, including patients with metastatic
disease, those deemed unresectable and ineligible for local
treatment, and those with local treatment failure. The
results for OS, PFS, and TTP mirrored or exceeded those
observed in the Sorafenib AP trial. For example, patients in
this trial had a median OS of 8.6 months (95% CI,
6.44–10.06 months) and a median TTP of 3.8 months
(95% CI, 2.63–4.08 months). In comparison, sorafenib-
treated patients in the AP trial had a median OS of
6.5 months (95% CI, 5.56–7.56 months) and a median TTP
of 2.8 months (95% CI, 2.63–3.58 months) [5]. However,
median OS and TTP in this trial were in line with the
sorafenib control arms of Asian patients in recent phase III
Table 3 Observed and
predicted sorafenib exposure in
patients over time
Type Time (months) nobs nind Geometric mean (mg/L) 95% CI Diff (%)
Observed 0–3 332 85 3.42 3.07–3.81 8.42
3–6 188 55 3.15 2.83–3.51 0
6–9 125 35 2.81 2.40–3.33 -10.7
9–12 95 25 2.47 2.11–2.88 -21.7
12–15 56 18 2.23 1.80–2.76 -29.4
15–18 31 9 1.84 1.34–2.52 -41.7
18–21 20 6 2.02 1.40–2.91 -36.0
Predicted 0–3 332 85 3.46 3.14–3.81 14.7
3–6 188 55 3.01 2.76–3.30 0
6–9 125 35 2.72 2.41–3.08 -9.62
9–12 95 25 2.62 2.33–2.94 -13.1
12–15 56 18 2.26 1.97–2.60 -25.0
15–18 31 9 2.00 1.61–2.48 -33.8
18–21 20 6 1.79 1.34–2.40 -40.6
Diff (%) the percentage difference in mean sorafenib exposure relative to the mean sorafenib exposure in
the 3- to 6-month period
CI confidence interval, nobs number of observations, nind number of individuals















Fig. 3 Observed and predicted sorafenib concentrations over time.
The final pharmacokinetics model predicted reductions in sorafenib
exposure of 13.1 and 33.8% over 6 and 12 months of treatment,
respectively, as shown by comparing the 3- to 6-month interval with
the 9- to 12- and 15- to 18-month intervals. Time was stratified by
quarter, with predicted concentrations representing individual values.
Data are presented as geometric means and 95% confidence intervals
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trials investigating sunitinib and brivanib in advanced HCC
[9, 10]. The trend toward longer survival of patients with
advanced HCC enrolled in current compared with earlier
clinical trials may be due to better disease characteristics at
enrollment and more physician experience handling the
AEs associated with sorafenib.
Patients with advanced HCC are prone to deterioration
of liver function, largely due to worsening of underlying
cirrhosis and/or progression of intrahepatic tumor lesions,
but in some patients the cause is drug-induced toxicity. The
median time for progression from Child–Pugh A to Child–
Pugh B or C was 2.9 months (95% CI, 1.87–4.8 months).
Nevertheless, median sorafenib concentrations in patients
progressing to Child–Pugh B or C were similar to those in
patients with Child–Pugh A, suggesting that sorafenib
exposure was not associated with Child–Pugh status. A
Table 4 Incidence of grade 3–5 treatment-emergent AEs reported for
[10% of patients in any study arm and incidence of HFSR and HFSR
scores in patients treated with corticosteroid and noncorticosteroid
ointments and in nonointment-treated patients from the HATT trial
registered prior to the beginning of the HFSR prevention substudy








Anemia 2 (6.9) 4 (11.8) 11 (12.5)
Abdominal pain 1 (3.4) 3 (8.8) 13 (14.8)
Ascites 3 (10.3) 2 (6.1) 13 (14.8)
Diarrheaa 3 (10.3) 5 (14.7) 11 (12.5)
Hepatic failure 1 (3.4) 1 (2.9) 12 (13.6)
Elevated alanine aminotransferase 3 (10.3) 2 (5.9) 12 (13.6)
Elevated aspartate
aminotransferase
4 (13.8) 5 (14.7) 24 (27.3)
Elevated blood bilirubin 3 (10.3) 4 (11.8) 19 (21.6)
Decreased platelet count 2 (6.9) 4 (11.8) 11 (12.5)
Hyponatremia 2 (6.9) 7 (20.6) 12 (13.6)
Hypophosphatemiaa 3 (10.3) 1 (2.9) 4 (4.5)
Encephalopathy 1 (3.4) 4 (11.8) 12 (13.6)
HFSRa 0 2 (5.9) 18 (20.5)
Hypertensiona 5 (17.2) 5 (14.7) 9 (10.2)
p valueb p valuec
HFSR, n (%)
3 weeks 10 (34.5) 16 (47.1) 0.1561 44 (50.0) 0.0730
6 weeks 15 (51.7) 20 (58.8) 0.2860 52 (59.1) 0.2434
Overall 16 (55.2) 24 (70.6) 0.1026 58 (65.9) 0.1492
Grade 3 HFSRa, n (%)
3 weeks 0 (0) 1 (2.9) N.D. 11 (12.5) N.D.
6 weeks 0 (0) 2 (5.9) N.D. 13 (14.8) N.D.
Overall 0 (0) 2 (5.9) N.D. 18 (20.5) N.D.
HFSR score
3 weeks 0.55 0.74 0.2026 0.86 0.0744
6 weeks 0.72 1.00 0.1159 1.03 0.0784
Overall 0.83 1.26 0.0314 1.24 0.0380
Median time to HFSR onset, d (range) 41 (1–238) 22 (5–145) 0.0639 21 0.0782
All p values are 1-sided
HFSR hand-foot skin reaction, N.D. not determined, TEAE treatment-emergent adverse events
a No grade 4 or 5 AEs were reported
b Comparisons of patients randomized to corticosteroid cream and noncorticosteroid ointments
c Comparisons of patients randomized to corticosteroid cream and those not treated with ointment
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small number of patients (n = 12) had Child–Pugh C
scores at the end of treatment. Although patient-level data
on causes for change from Child–Pugh A to Child–Pugh C
score were not collected, most patients who discontinued
sorafenib therapy had disease progression. Disease pro-
gression may be a key contributor to the change from
Child–Pugh A to Child–Pugh C, although a separate
prospective study is needed to determine predictors of
change in Child–Pugh score in patients on sorafenib
treatment. Of note, consistent progression over time in
Child–Pugh scores (i.e., from A to B, B to C, and A to C)
was not observed in all patients. Instead, in some patients,
Child–Pugh scores varied within patients over time, with
some patients showing improvements after initial worsen-
ing and others demonstrating progressive deterioration.
Application of a population pharmacokinetic model
suggested that sorafenib concentrations tended to decrease
over time. Concentrations of albumin and bilirubin were
positively correlated with sorafenib concentrations,
although only bilirubin concentration showed a time
dependence, possibly due to sorafenib inhibiting metabo-
lism of bilirubin by UGT1A1 [11]. The final pharmacoki-
netic model predicted decreases in sorafenib exposure over
6 and 12 months of 13.1 and 33.8%, respectively. This
change in concentration was not associated with reductions
in liver function, as shown by Child–Pugh score, nor was it
due to reductions or interruptions in sorafenib dosing. The
mechanisms underlying these reductions in sorafenib
exposure, and the clinical impact of these reductions, have
not yet been determined. Nonlinear mixed effects modeling
using NONMEM is based on datasets containing the actual
doses taken and, should they occur, naturally adjusts the
model predictions for dosing changes. Because the model
predictions insufficiently accounted for reductions in
observed concentrations, the changes are therefore caused
by factors other than dosing reductions/interruptions.
Hand-foot skin reaction
HFSR is a frequent AE of tyrosine kinase inhibitors,
including sorafenib, that target the vascular endothelial
growth factor signaling pathway [5, 6, 12–16]. Topical
steroids have been reported effective in the treatment of
sorafenib-induced HFSR [17–19]. Analysis of incidence,
time to HFSR, and HFSR score in a subset of patients in
this study randomized to a corticosteroid or a noncorti-
costeroid cream found that those randomized to the corti-
costeroid cream tended to have a longer time to onset of
HFSR and a better HFSR score than patients randomized to
the noncorticosteroid cream, although most differences
were not statistically significant. Interestingly, although the
initial cohort of patients not prescribed ointment before the
randomized HFSR prevention substudy had similar HFSR
incidence, time to HFSR, and HFSR scores as patients
randomized to noncorticosteroid cream, the incidence of
grade 3 HFSR was noticeably lower in the noncorticos-
teroid cream group than in the nonointment group (i.e., the
initial 88 nonrandomized patients), potentially supporting
the value of any type of ointment for HFSR prophylaxis. A
recent trial involving 871 Chinese patients treated for HCC
found that prophylactic administration of a urea-based
cream significantly reduced the 12-week incidence of any
grade HFSR (56.0% vs. 73.6%; OR, 0.457; 95% CI,
0.344–0.608; p\ 0.0001) and of grade C 2 HFSR (20.7%
vs. 29.2%%; OR, 0.635; 95% CI, 0.466–0.866; p = 0.004)
compared with best-supportive care alone [19]. Moreover,
the median time to first occurrence of HFSR was signifi-
cantly longer in the urea-based cream than in the control
group (84 vs. 34 days; hazard ratio, 0.658; 95% CI,
0.541–0.799; p\ 0.0001). Taken together, these findings
suggest that prophylactic treatment with a urea-based or
corticosteroid-containing cream may benefit patients being
treated with sorafenib for HCC.
Although, in the main study, AEs such as HFSR, ascites,
and diarrhea were frequent, all were manageable and rarely
resulted in discontinuation from treatment. There were no
new or unexpected safety findings.
In conclusion, the outcome of this study confirms the
results of the previous Sorafenib AP study. The pharma-
cokinetic model predicted decreases in sorafenib exposure,
but the clinical significance of the observed 33.8% decrease
in exposure after 1 year remains unclear, especially given
the shorter median and mean treatment duration in this
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Fig. 4 Kaplan–Meier analysis of time to HFSR in sorafenib-treated
HCC patients randomized to corticosteroid (n = 29) and noncorti-
costeroid (n = 34) ointments and in nonointment-treated patients
from the HATT trial registered before the beginning of the HFSR
prevention substudy (n = 88). HFSR hand-foot skin reaction, HCC
hepatocellular carcinoma, HATT Hepatocellular Carcinoma–Ad-
vanced Stage–Sorafenib Trial in Taiwanese patients
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patient population. Sorafenib remains the standard of care
for Asian patients with advanced/metastatic HCC.
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